Efficacy of bretylium tosylate for ventricular tachycardia.

Abstract

In 20 patients with inducible ventricular tachycardia (VT), intravenous bretylium tosylate infused as a 10-mg/kg bolus followed by 2 mg/min caused no change in refractory periods and did not suppress inducibility of VT. The use of bretylium for the treatment of VT should be reexamined.

• Authors: S Chandrasekaran, J S Steinberg
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 83 Issue 1 Pg. 115-7, A9 (Jan 01 1999) ISSN: 0002-9149 [Print] United States
• PMID: 10073797 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Arrhythmia Agents
• Bretylium Tosylate

Topics

• Anti-Arrhythmia Agents (adverse effects, therapeutic use)
• Bretylium Tosylate (adverse effects, therapeutic use)
• Female
• Hemodynamics (drug effects)
• Humans
• Hypotension (chemically induced)
• Male
• Middle Aged
• Prospective Studies
• Severity of Illness Index
• Syncope (etiology, physiopathology, prevention & control)
• Tachycardia, Ventricular (complications, drug therapy, physiopathology)
• Treatment Failure